CD4 and cancer: Further studies have revealed that TILs, such as CD8+ T cells and CD4+ T cells, including Foxp3+CD4+ T cells subset, are known to induce PD-L1 expression on tumour and immune cells in a number of types of cancers, including NSCLC [79,90].